Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review
- PMID: 29496075
- DOI: 10.1016/j.ejrad.2018.01.012
Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review
Abstract
Objective: To evaluate the value of yttrium-90 (90Y) microspheres in the management of unresectable liver metastases secondary to neuroendocrine tumors (NETs).
Materials and methods: PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and the "gray" literature (Google Scholar) were searched for all studies related to 90Y therapy for unresectable liver metastases of NETs.
Results: A total of 11 studies and 7 abstracts involving 870 patients were included in the final analysis. In 11 of these studies, 19.8% (77/388) of patients had undergone transarterial bland embolization (TABE) or transarterial chemoembolization (TACE) before 90Y therapy. The median disease control rate among all patients was 86% at 3 months after 90Y therapy. The median survival was 28 months, with 1-, 2-, and 3-year survival rates of 72.5%, 57%, and 45%, respectively. The median survival values for patients who received resin- and glass-based 90Y treatment were 27.6 and 31.7 months, respectively. The survival values for patients with carcinoid, pancreatic, and unclassified origin of NETs were 56, 31, and 28 months, respectively; the survival values for patients with grade I, II, and III NETs were 71, 56, and 28 months, respectively. Carcinoid syndrome was reported in 52.4% (55/105) of patients, and 69.1% of those with clinical symptoms demonstrated improvement in symptoms after 90Y radioembolization. Complications were reported in 9 studies, including radiation gastritis (n = 4), duodenal ulcer (n = 2), death due to liver failure (n = 1), and radiation cholecystitis (n = 1). The most common side effects were abdominal pain (median, 32.6%), nausea/vomiting (median, 32.5%), and fatigue (median, 30.4%).
Conclusions: 90Y radioembolization can be used as an alternative therapy for unresectable liver metastases of NETs, with an improved survival rate and tumor response. This treatment is also effective for patients who have undergone unsuccessful TABE/TACE therapy and for the relief of symptoms in patients with carcinoid syndrome.
Keywords: Liver metastases; Neuroendocrine tumor; Radioembolization; Yttrium-90.
Copyright © 2018. Published by Elsevier B.V.
Similar articles
-
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.Cancer. 2008 Sep 1;113(5):921-9. doi: 10.1002/cncr.23685. Cancer. 2008. PMID: 18618495 Clinical Trial.
-
A systematic review of yttrium-90 radioembolization for unresectable liver metastases of melanoma.Eur J Radiol. 2017 Jul;92:111-115. doi: 10.1016/j.ejrad.2017.05.005. Epub 2017 May 4. Eur J Radiol. 2017. PMID: 28624008 Review.
-
Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.J Gastroenterol Hepatol. 2017 Sep;32(9):1617-1623. doi: 10.1111/jgh.13752. J Gastroenterol Hepatol. 2017. PMID: 28132407
-
Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.Cardiovasc Intervent Radiol. 2012 Apr;35(2):334-42. doi: 10.1007/s00270-011-0248-1. Epub 2011 Aug 17. Cardiovasc Intervent Radiol. 2012. PMID: 21847708
-
A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.Saudi J Gastroenterol. 2016 Sep-Oct;22(5):353-359. doi: 10.4103/1319-3767.191139. Saudi J Gastroenterol. 2016. PMID: 27748320 Free PMC article. Review.
Cited by
-
[Radiologically guided interventional therapies for the treatment of neuroendocrine tumors].Radiologie (Heidelb). 2024 Jul;64(7):575-581. doi: 10.1007/s00117-024-01314-z. Epub 2024 May 18. Radiologie (Heidelb). 2024. PMID: 38761204 German.
-
Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Curr Oncol. 2024 Apr 5;31(4):2076-2091. doi: 10.3390/curroncol31040154. Curr Oncol. 2024. PMID: 38668057 Free PMC article. Review.
-
Neuroendocrine Tumors: Genomics and Molecular Biomarkers with a Focus on Metastatic Disease.Cancers (Basel). 2023 Apr 12;15(8):2249. doi: 10.3390/cancers15082249. Cancers (Basel). 2023. PMID: 37190177 Free PMC article. Review.
-
Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases.J Clin Med. 2023 Mar 23;12(7):2456. doi: 10.3390/jcm12072456. J Clin Med. 2023. PMID: 37048539 Free PMC article. Review.
-
Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.Tomography. 2023 Jan 27;9(1):217-246. doi: 10.3390/tomography9010018. Tomography. 2023. PMID: 36828370 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous